Abstract
Risk classification of early-stage breast cancer patients by gene expression profiling can result in substantial drug cost savings. Economic analyses suggest that appropriate use of clinically validated molecular diagnostics offers the potential for cost savings and improved patient quality of life.
| Original language | English |
|---|---|
| Pages (from-to) | 9-12; discussion 17-18 |
| Journal | Managed care (Langhorne, Pa.) |
| Volume | 17 |
| Issue number | 7 Suppl 7 |
| State | Published - Jul 2008 |
UN SDGs
This output contributes to the following UN Sustainable Development Goals (SDGs)
-
SDG 3 Good Health and Well-being
ASJC Scopus subject areas
- Health Policy
- Public Health, Environmental and Occupational Health
Fingerprint
Dive into the research topics of 'Assessing therapeutically developed assays.'. Together they form a unique fingerprint.Cite this
- APA
- Author
- BIBTEX
- Harvard
- Standard
- RIS
- Vancouver